Here's Why Karyopharm Therapeutics Is Sliding on Tuesday

Shares of Karyopharm Therapeutics (NASDAQ: KPTI), a biopharmaceutical company developing new cancer drugs, are tanking Tuesday as investors respond to an unexpected leadership change.

The stock was trading 30.5% lower as of 11:52 a.m. ET. 

On Feb. 8, shares of Karyopharm slipped after the company posted lackluster clinical trial results for its lead drug, Xpovio, as a potential treatment for endometrial cancer. The drug is already approved to treat multiple myeloma patients whose conditions worsen despite previous lines of treatment.

Continue reading

Source Fool.com